Integrated CRDMO Services for Nucleic Acid Therapeutics
Single-source RNA therapeutics platform offering lead identification and bioanalytics, process development, as well as GMP manufacturing
Core Focus
Lead identification and chemistry optimisation for therapeutic oligonucleotides using bioinformatics-driven design and early in vitro screening.
Expertise
Proprietary sequence selection algorithms, high-throughput screening and RNA-Seq-based off-target analysis to optimise lead candidates. Our Kulmbach facility’s deep bioinformatics platform and multiplex screening accelerate candidate validation, minimise risks, and prioritise high-potential leads.
Impact
Speeds early-stage development, reducing attrition by ensuring lead candidates are chemically optimised and biologically validated.
Core Focus
Conducting preclinical safety, pharmacokinetics, and biodistribution studies, along with early synthesis and process development to support IND/CTA submissions.
Expertise
Solid-phase oligonucleotide synthesis and conjugates, GLP-compliant bioanalysis (proprietary PNA assay), LC-MS/MS assays, and advanced cell-based functional testing.
Impact
Delivers regulatory-aligned data, streamlines toxicology and immunogenicity evaluations, and ensures a smooth path to clinical trials.
Core Focus
Non-GMP to GMP manufacturing, process development, and synthesis scale-up for toxicology studies, bridging the gap between discovery and clinical readiness.
Expertise
Synthesis of chemically modified oligonucleotides and their conjugates utilizing advanced in-process controls and comprehensive impurity profiling based on tailored analytical methods.
Impact
Enables efficient scale-up, technical validation, and seamless transfer to GMP production by de-risking manufacturing processes early.
Core Focus
GMP-compliant production of nucleic acid therapeutics (ASOs, siRNA, sgRNA, aptamers, and their complex bioconjugates), providing a reliable supply for clinical trial phases I–III and initial commercial requirements.
Expertise
Dual-site, globally integrated facilities (Petaluma, USA, and Berlin, Germany), equipped with Cytiva OligoPilot™, OligoProcess™, and advanced Asahi Kasei Bioprocess (AKB THESYS™) platforms. Comprehensive analytics, in-line process monitoring, and regulatory-compliant validation.
Impact
Delivers scalable, high-purity therapeutic supply with robust quality assurance and seamless integration between clinical development and initial commercialisation phases.
Meet us
Get to know the team behind Axolabs, where innovation meets collaboration. Meet the scientists, technical experts, and industry leaders dedicated to advancing oligonucleotide therapeutics and delivering excellence at every stage of development.
Join us
Join a global leader in oligonucleotide research and development. At Axolabs, you’ll work with state-of-the-art technologies, collaborate with world-class experts, and contribute to shaping the future of nucleic acid therapeutics. Explore career opportunities today.